Skip to Content
Merck
  • Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging.

Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging.

Radiology (1987-05-01)
A J Dwyer, J A Frank, J L Doppman, E H Oldfield, A M Hickey, G B Cutler, D L Loriaux, T F Schiable
ABSTRACT

To assess the role of magnetic resonance imaging in the evaluation of adrenocorticotropic-hormone (ACTH)-producing pituitary adenomas, and the effect of intravenously administered gadolinium-diethylenetriaminepentaacetic acid (DTPA) on lesion/pituitary contrast, imaging was performed in 13 patients with clinical and chemical evidence of Cushing disease. Images were obtained at 0.5 T before and after the injection of Gd-DTPA (0.1 mmol/kg). Lesions were identified in eight of 12 precontrast and ten of 12 postcontrast studies. In these 12 patients adenomas were found at transsphenoidal surgery. The other patient, with normal images, was found to have an ectopic source of ACTH. Coronal images corresponded remarkably well with the neurosurgeon's intraoperative findings. Serial T1-weighted images disclosed early enhancement of the pituitary gland and delayed enhancement of the cystic adenomas. The discrepancy in times to peak enhancement accounted for improved lesion/pituitary contrast in some early images and for reversal or diminution of lesion/pituitary contrast in later images.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Diethylenetriaminepentaacetic acid gadolinium(III) dihydrogen salt hydrate, 97%